IRONWOOD PHARMACEUTICALS INC 8-K

What Happened
Ironwood Pharmaceuticals, Inc. announced on June 15, 2026 that it repaid in full the $200.0 million aggregate principal amount of its 1.50% convertible senior notes due 2026 at their scheduled maturity. The company funded the repayment using available cash on hand. No conversions were exercised by holders of the notes, and the capped call transactions entered in connection with the issuance of the notes terminated upon expiry.

Key Details

• Repayment amount: $200.0 million aggregate principal of 1.50% convertible senior notes due 2026.
• Repayment date: June 15, 2026 (scheduled maturity).
• Funding source: available cash on hand (no new financing disclosed).
• Conversions and hedges: no conversions were exercised by noteholders; related capped call transactions terminated upon expiry.

Why It Matters
The repayment removes the convertible notes from Ironwood’s outstanding debt and eliminates the potential for those notes to convert into equity, so there is no dilution from these instruments. It also reflects a use of the company’s cash resources to satisfy a scheduled debt obligation; investors should note this reduced liability on the balance sheet and that cash reserves were used for the repayment. The termination of the capped calls ends the related hedge positions that were tied to these securities.